NTLA

SEC source: 0001209191-23-002433 · doc4.xml · nonDerivative · entry 1

Sepp-Lorenzino Laura · CIK 0001777421 · EVP, Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,959

F1 · kind: Shares sold in sell-to-cover transaction in order to satisfy withholding taxes to be paid upon the vesting of RSUs on January 1, 2023.

SEC source: 0001209191-23-002425 · doc4.xml · nonDerivative · entry 1

LEONARD JOHN M · CIK 0001563584 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 766,825

F1 · date: Shares sold in sell-to-cover transaction in order to satisfy withholding taxes to be paid upon the vesting of RSUs on January 1, 2023.

SEC source: 0001209191-23-002414 · doc4.xml · nonDerivative · entry 1

Goddard Glenn · CIK 0001581992 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,404

F1 · kind: Shares sold in sell-to-cover transaction in order to satisfy withholding taxes to be paid upon the vesting of RSUs on January 1, 2023.

SEC source: 0001209191-23-002421 · doc4.xml · nonDerivative · entry 1

Hicks Derek · CIK 0001901282 · EVP, Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,306

F1 · kind: Shares sold in sell-to-cover transaction in order to satisfy withholding taxes to be paid upon the vesting of RSUs on January 3, 2023.

SEC source: 0001209191-23-002412 · doc4.xml · nonDerivative · entry 3

Clark Eliana · CIK 0001914448 · EVP, Chief Technical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,473

F3 · kind: Shares sold in sell-to-cover transaction in order to satisfy withholding taxes to be paid upon the vesting of RSUs on January 1, 2023.

SEC source: 0001209191-23-002410 · doc4.xml · nonDerivative · entry 1

BASTA JAMES · CIK 0001792726 · EVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,559

F1 · kind: Shares sold in sell-to-cover transaction in order to satisfy withholding taxes to be paid upon the vesting of RSUs on January 1, 2023.

SEC source: 0001209191-23-002412 · doc4.xml · nonDerivative · entry 2

Clark Eliana · CIK 0001914448 · EVP, Chief Technical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,165

F2 · kind: Sale of 231 shares that were acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on December 31, 2022.

SEC source: 0001209191-23-001492 · doc4.xml · derivative · entry 2

Lebwohl David · CIK 0001810882 · EVP, Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,376

Underlying: Common Stock · 3,187 shares

Expires 2031-03-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.

F3 · derivative.exercise_date: On March 3, 2021, the reporting person was granted 12,750 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments thereafter.

F3 · derivative.expiration_date: On March 3, 2021, the reporting person was granted 12,750 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments thereafter.

SEC source: 0001209191-23-001492 · doc4.xml · nonDerivative · entry 1

Lebwohl David · CIK 0001810882 · EVP, Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,261

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.

F2 · balance_after: Includes 105 and 231 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on June 30, 2022 and December 31, 2022, respectively.

SEC source: 0001209191-23-001498 · doc4.xml · derivative · entry 2

Sepp-Lorenzino Laura · CIK 0001777421 · EVP, Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,000

Underlying: Common Stock · 3,500 shares

Expires 2031-03-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.

F3 · derivative.exercise_date: On March 3, 2021, the reporting person was granted 14,000 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments thereafter.

F3 · derivative.expiration_date: On March 3, 2021, the reporting person was granted 14,000 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments thereafter.

SEC source: 0001209191-23-001498 · doc4.xml · nonDerivative · entry 1

Sepp-Lorenzino Laura · CIK 0001777421 · EVP, Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,467

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.

F2 · balance_after: Includes 105 and 231 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on June 30, 2022 and December 31, 2022, respectively.

SEC source: 0001209191-23-001495 · doc4.xml · derivative · entry 3

LEONARD JOHN M · CIK 0001563584 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,698

Underlying: Common Stock · 7,848 shares

Expires 2031-03-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.

F3 · derivative.exercise_date: On March 3, 2021, the reporting person was granted 31,394 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments thereafter.

F3 · derivative.expiration_date: On March 3, 2021, the reporting person was granted 31,394 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments thereafter.

SEC source: 0001209191-23-001495 · doc4.xml · nonDerivative · entry 1

LEONARD JOHN M · CIK 0001563584 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 773,498

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.

SEC source: 0001209191-23-001490 · doc4.xml · derivative · entry 2

Goddard Glenn · CIK 0001581992 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,126

Underlying: Common Stock · 3,062 shares

Expires 2031-03-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.

F2 · derivative.exercise_date: On March 3, 2021, the reporting person was granted 12,250 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments thereafter.

F2 · derivative.expiration_date: On March 3, 2021, the reporting person was granted 12,250 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments thereafter.

SEC source: 0001209191-23-001490 · doc4.xml · nonDerivative · entry 1

Goddard Glenn · CIK 0001581992 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,831

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.

SEC source: 0001209191-23-002412 · doc4.xml · nonDerivative · entry 1

Clark Eliana · CIK 0001914448 · EVP, Chief Technical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,165

F1 · kind: Sale of 105 shares that were acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on June 30, 2022.

SEC source: 0001209191-22-037598 · doc4.xml · derivative · entry 2

FORMELA JEAN FRANCOIS · CIK 0001030575 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,688

Underlying: Common Stock · 7,688 shares

Expires 2032-06-13

F2 · derivative.exercise_date: This option was granted on June 14, 2022 with respect to 7,688 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.

F3 · ownership.direct: The reporting person is a member of Atlas Venture Associates IX, LLC ("AVA IX LLC") and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the equity grants to Atlas Venture Advisors, L.P. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.

SEC source: 0001209191-22-037598 · doc4.xml · nonDerivative · entry 1

FORMELA JEAN FRANCOIS · CIK 0001030575 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,291

F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.

SEC source: 0001209191-22-037595 · doc4.xml · derivative · entry 2

DORSA CAROLINE · CIK 0001181174 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,688

Underlying: Common Stock · 7,688 shares

Expires 2032-06-13

F2 · derivative.exercise_date: This option was granted on June 14, 2022 with respect to 7,688 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.

SEC source: 0001209191-22-037595 · doc4.xml · nonDerivative · entry 1

DORSA CAROLINE · CIK 0001181174 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,701

F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.

SEC source: 0001209191-22-037600 · doc4.xml · derivative · entry 2

GOODMAN JESSE · CIK 0001756929 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,688

Underlying: Common Stock · 7,688 shares

Expires 2032-06-13

F2 · derivative.exercise_date: This option was granted on June 14, 2022 with respect to 7,688 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.

SEC source: 0001209191-22-037600 · doc4.xml · nonDerivative · entry 1

GOODMAN JESSE · CIK 0001756929 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,291

F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.

SEC source: 0001209191-22-037604 · doc4.xml · derivative · entry 2

Verwiel Frank · CIK 0001545794 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,688

Underlying: Common Stock · 7,688 shares

Expires 2032-06-13

F2 · derivative.exercise_date: This option was granted on June 14, 2022 with respect to 7,688 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.

SEC source: 0001209191-22-037604 · doc4.xml · nonDerivative · entry 1

Verwiel Frank · CIK 0001545794 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,291

F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.

SEC source: 0001209191-22-037602 · doc4.xml · derivative · entry 2

Keresty Georgia · CIK 0001773532 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,688

Underlying: Common Stock · 7,688 shares

Expires 2032-06-13

F2 · derivative.exercise_date: This option was granted on June 14, 2022 with respect to 7,688 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.

SEC source: 0001209191-22-037602 · doc4.xml · nonDerivative · entry 1

Keresty Georgia · CIK 0001773532 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,721

F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.

SEC source: 0001209191-22-037592 · doc4.xml · derivative · entry 2

Crowley John F · CIK 0001400973 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,688

Underlying: Common Stock · 7,688 shares

Expires 2032-06-13

F2 · derivative.exercise_date: This option was granted on June 14, 2022 with respect to 7,688 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.

SEC source: 0001209191-22-037592 · doc4.xml · nonDerivative · entry 1

Crowley John F · CIK 0001400973 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,291

F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.

SEC source: 0001209191-22-037590 · doc4.xml · derivative · entry 2

Cohen Fred E · CIK 0001339358 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,688

Underlying: Common Stock · 7,688 shares

Expires 2032-06-13

F2 · derivative.exercise_date: This option was granted on June 14, 2022 with respect to 7,688 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.

SEC source: 0001209191-22-037590 · doc4.xml · nonDerivative · entry 1

Cohen Fred E · CIK 0001339358 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,291

F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.

SEC source: 0001209191-22-037588 · doc4.xml · derivative · entry 2

Bhanji Muna · CIK 0001846905 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,980

Underlying: Common Stock · 2,980 shares

Expires 2032-06-13

F2 · derivative.exercise_date: This option was granted on June 14, 2022 with respect to 2,980 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.

SEC source: 0001209191-22-037588 · doc4.xml · nonDerivative · entry 1

Bhanji Muna · CIK 0001846905 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,968

F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.

SEC source: 0001209191-22-026561 · doc4.xml · derivative · entry 2

Bhanji Muna · CIK 0001846905 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,700

Underlying: Common Stock · 11,700 shares

Expires 2032-04-27

F2 · derivative.exercise_date: This option was granted on April 28, 2022 with respect to 11,700 shares of Common Stock pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan, with 33 1/3 % vesting on April 28, 2023 and the remaining 66 2/3% vesting in 8 substantially equal quarterly installments thereafter.

SEC source: 0001209191-22-026561 · doc4.xml · nonDerivative · entry 1

Bhanji Muna · CIK 0001846905 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,954

F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.

SEC source: 0001209191-22-015960 · doc4.xml · derivative · entry 5

Lebwohl David · CIK 0001810882 · EVP, Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,816

Underlying: Common Stock · 13,816 shares

Expires 2032-02-28

F6 · derivative.exercise_date: This option was granted on March 1, 2022 with respect to shares of Common Stock, with 33% vesting on January 1, 2023 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter.

SEC source: 0001209191-22-015960 · doc4.xml · nonDerivative · entry 3

Lebwohl David · CIK 0001810882 · EVP, Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,738

F4 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.

SEC source: 0001209191-22-015976 · doc4.xml · derivative · entry 5

Sepp-Lorenzino Laura · CIK 0001777421 · EVP, Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,816

Underlying: Common Stock · 13,816 shares

Expires 2032-02-28

F6 · derivative.exercise_date: This option was granted on March 1, 2022 with respect to shares of Common Stock, with 33% vesting on January 1, 2023 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter.

SEC source: 0001209191-22-015976 · doc4.xml · nonDerivative · entry 3

Sepp-Lorenzino Laura · CIK 0001777421 · EVP, Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,631

F4 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.

SEC source: 0001209191-22-015917 · doc4.xml · derivative · entry 5

Goddard Glenn · CIK 0001581992 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,720

Underlying: Common Stock · 12,720 shares

Expires 2032-02-28

F5 · derivative.exercise_date: This option was granted on March 1, 2022 with respect to shares of Common Stock, with 33% vesting on January 1, 2023 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter.

SEC source: 0001209191-22-015917 · doc4.xml · nonDerivative · entry 3

Goddard Glenn · CIK 0001581992 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,769

F3 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.

SEC source: 0001209191-22-015909 · doc4.xml · derivative · entry 3

BASTA JAMES · CIK 0001792726 · EVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,648

Underlying: Common Stock · 9,648 shares

Expires 2032-02-28

F2 · derivative.exercise_date: This option was granted on March 1, 2022 with respect to shares of Common Stock, with 33% vesting on January 1, 2023 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter.

SEC source: 0001209191-22-015909 · doc4.xml · nonDerivative · entry 2

BASTA JAMES · CIK 0001792726 · EVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,697

F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.

SEC source: 0001209191-22-015909 · doc4.xml · nonDerivative · entry 1

BASTA JAMES · CIK 0001792726 · EVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,049

F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.

SEC source: 0001209191-22-016533 · doc4a.xml · derivative · entry 1

Lebwohl David · CIK 0001810882 · EVP, Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,203

Underlying: Common Stock · 20,203 shares

Expires 2032-02-28

F1 · shares: The original Form 4 incorrectly reported the number of options granted as 13,816.

F2 · derivative.exercise_date: This option was granted on March 1, 2022 with respect to shares of Common Stock, with 33% vesting on January 1, 2023 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter.

F1 · derivative.underlying_shares: The original Form 4 incorrectly reported the number of options granted as 13,816.

F1 · balance_after: The original Form 4 incorrectly reported the number of options granted as 13,816.

SEC source: 0001209191-22-016526 · doc4a.xml · derivative · entry 1

Sepp-Lorenzino Laura · CIK 0001777421 · EVP, Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,203

Underlying: Common Stock · 20,203 shares

Expires 2032-02-28

F1 · shares: The original Form 4 incorrectly reported the number of options granted as 13,816.

F2 · derivative.exercise_date: This option was granted on March 1, 2022 with respect to shares of Common Stock, with 33% vesting on January 1, 2023 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter.

F1 · derivative.underlying_shares: The original Form 4 incorrectly reported the number of options granted as 13,816.

F1 · balance_after: The original Form 4 incorrectly reported the number of options granted as 13,816.

SEC source: 0001209191-22-016539 · doc4a.xml · derivative · entry 1

BASTA JAMES · CIK 0001792726 · EVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,109

Underlying: Common Stock · 14,109 shares

Expires 2032-02-28

F1 · shares: The original Form 4 incorrectly reported the number of options granted as 9,648.

F2 · derivative.exercise_date: This option was granted on March 1, 2022 with respect to shares of Common Stock, with 33% vesting on January 1, 2023 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter.

F1 · derivative.underlying_shares: The original Form 4 incorrectly reported the number of options granted as 9,648.

F1 · balance_after: The original Form 4 incorrectly reported the number of options granted as 9,648.

SEC source: 0001209191-22-016537 · doc4.xml · derivative · entry 6

LEONARD JOHN M · CIK 0001563584 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,941

Underlying: Common Stock · 59,941 shares

Expires 2032-02-28

F6 · derivative.exercise_date: This option was granted on March 1, 2022 with respect to shares of Common Stock, with 33% vesting on January 1, 2023 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter.

SEC source: 0001209191-22-016537 · doc4.xml · nonDerivative · entry 3

LEONARD JOHN M · CIK 0001563584 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 765,650

F3 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.

SEC source: 0001209191-22-016535 · doc4a.xml · derivative · entry 1

Goddard Glenn · CIK 0001581992 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,600

Underlying: Common Stock · 18,600 shares

Expires 2032-02-28

F1 · shares: The original Form 4 incorrectly reported the number of options granted as 12,720.

F2 · derivative.exercise_date: This option was granted on March 1, 2022 with respect to shares of Common Stock, with 33% vesting on January 1, 2023 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter.

F1 · derivative.underlying_shares: The original Form 4 incorrectly reported the number of options granted as 12,720.

F1 · balance_after: The original Form 4 incorrectly reported the number of options granted as 12,720.

SEC source: 0001209191-22-016851 · doc4.xml · derivative · entry 2

Clark Eliana · CIK 0001914448 · EVP, Chief Technical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,395

Underlying: Common Stock · 15,395 shares

Expires 2032-02-28

F2 · derivative.exercise_date: This option was granted on March 1, 2022 with respect to shares of Common Stock, with 33% vesting on January 1, 2023 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter.